RE: AstraZeneca and Sanofi $810M of payment lined up4 Jan 2024 13:21
The market potential in immuno-inflammation is large and growing, reflecting the need for better treatments. With a robust balance sheet, focused strategy and streamlined portfolio, we believe we are strongly positioned in immuno-inflammation and excited about the future.
On the out-licensed programme, the company noted that Sanofi is making progress on the IL-17A inhibitor programme for inflammatory diseases towards the next milestone.
Of its portfolio of early-stage discovery immuno-inflammatory molecules, the board still anticipates moving two projects into lead optimisation by the end of 2024, following the project initiation process assessment involving C4X’s proprietary platforms, Conformetrix and PatientSeek, together with a thorough analysis of the commercial viability.
PatientSeek was launched in February to optimise patient selection, with the potential to match the most effective treatments with groups of patients who are most likely to benefit thereby ensuring the right drug is given to the right patient, based on their genetics.